Livraison suivie dans le monde entier | Env. 9–14 jours ouvrés

Votre panier

Votre panier est vide

Commencer à parcourir

Livraison gratuite pour les commandes de plus de €500.

Sous-total€0
Passer à la caisse
PerformanceMédicament approuvé

SS-31

Recherche publiée et base de preuves

Elamipretide (SS-31, MTP-131) is a mitochondria-targeted tetrapeptide that binds cardiolipin in the inner mitochondrial membrane, stabilising cristae architecture and improving electron transport efficiency and ATP synthesis. It has been studied in randomised controlled trials in Barth syndrome, primary mitochondrial myopathy, heart failure with reduced ejection fraction, Leber hereditary optic neuropathy and ischaemia-reperfusion settings, with mixed results: the Barth syndrome programme showed sustained functional gains in a small cohort, while the phase 3 MMPOWER-3 trial in primary mitochondrial myopathy missed its primary endpoints. On 19 September 2025 the FDA granted accelerated approval to elamipretide (FORZINITY, NDA 215244, Stealth BioTherapeutics) to improve muscle strength in adult and paediatric patients with Barth syndrome weighing at least 30 kg, based on an improvement in knee extensor muscle strength; continued approval is contingent on confirmatory trials. Evidence for use in healthy individuals or for athletic performance is absent.

En bref
  • SS-31 est un peptide ciblant les mitochondries qui se lie à la cardiolipine.
  • Des essais humains dans le syndrome de Barth ont montré des gains de force musculaire dans un petit groupe.
  • Aucune étude ne l'a testé chez des personnes en bonne santé pour la performance ou la longévité.

36 études · 21 depuis 2023 · plus récente 2026

Études citées
36
Publiées 2023+
21
Article le plus récent
2026
Dernière révision
oct. 2026

Thèmes récurrents dans la littérature

  • cardiolipin binding
  • mitochondrial cristae stabilisation
  • ATP synthesis and bioenergetics
  • Barth syndrome
  • primary mitochondrial myopathy
  • heart failure and cardiac bioenergetics
  • six-minute walk test
  • ischaemia-reperfusion injury
  • skeletal muscle fatigue
  • mitochondria-targeted tetrapeptide

Identifiants du composé

CAS
736992-21-5
PubChem
11764719

Identité chimique

Ce qu'est SS-31, chimiquement.

Formule moléculaire
C32H49N9O5
Masse moléculaire
639.8 g/mol
Numéro CAS
736992-21-5
PubChem CID
11764719
Également écrit

Elamipretide, bendavia, Ocuvia

Ces chiffres proviennent de la fiche PubChem pour ce composé et décrivent la base libre. Le peptide lyophilisé est normalement fourni sous forme de sel d'acétate ou de trifluoroacétate et contient de l'eau résiduelle, donc la masse de poudre dans un flacon ne correspond pas à la quantité suggérée par la masse moléculaire ci-dessus. La pureté chromatographique sur un certificat d'analyse ne résout pas cette différence non plus — comment lire un certificat d'analyse explique pourquoi.

Les preuves

36 études publiées.

Classées par rigueur du protocole d'étude, puis par date. Chaque entrée renvoie à sa source pour que les résultats puissent être vérifiés dans l'article plutôt que pris sur parole.

  1. 01Revue systématique2022

    Effect of mitochondrial-targeted antioxidants on glycaemic control, cardiovascular health, and oxidative stress in humans: A systematic review and meta-analysis of randomized controlled trials.

    Mason SA, et al. · Diabetes Obes Metab · systematic review and meta-analysis of 19 RCTs (n=884) of mitochondria-targeted antioxidants including elamipretide, MitoQ and MitoTEMPO

    Mitochondria-targeted antioxidants improved brachial flow-mediated dilation (very low certainty) but showed no significant effect on other glycaemic, cardiovascular or oxidative-stress outcomes; no serious treatment-emergent adverse events were reported, though subcutaneous elamipretide increased mild-to-moderate injection-site events.

    Résultat de sécurité signalé. Subcutaneous elamipretide was associated with more mild-to-moderate injection-site reactions.

  2. 02Clinique humaine2026

    Elamipretide in pediatric Barth syndrome: from heart failure to school return

    Amedro P, et al. · Orphanet Journal of Rare Diseases · Single-patient compassionate-use case report; 5-year-old with genetically confirmed Barth syndrome and severe heart failure

    Left ventricular ejection fraction rose from 20% to 50% during compassionate-use elamipretide, the child returned to full-time school and was temporarily suspended from the transplant list. As a single case report this cannot establish efficacy.

  3. 03Clinique humaine2025

    Initial Psychometric Evaluation of the Barth Syndrome Symptom Assessment (BTHS-SA) for Adolescents and Adults in a Phase 2 Clinical Study

    Gwaltney C, et al. · Orphanet Journal of Rare Diseases · Psychometric analysis nested in a phase 2 randomised, double-blind, placebo-controlled crossover elamipretide study; 12 male patients with Barth syndrome

    The Barth Syndrome Symptom Assessment produced reliable scores in this cohort, supporting its use as a patient-reported outcome measure in elamipretide trials.

  4. 04Clinique humaine2025

    ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.

    Ehlers JP, et al. · Ophthalmol Sci · phase 2 randomised double-masked placebo-controlled multicentre trial (ReCLAIM-2), n=176 with dry AMD and noncentral geographic atrophy, 48 weeks

    Elamipretide did not meet the primary endpoints (low-luminance visual acuity and geographic atrophy growth) but reduced progression of total and partial ellipsoid-zone loss by 43% and 47% versus placebo (nominal p values), and more patients gained at least 10 letters of low-luminance acuity; injection-site reactions were the most common adverse events.

    Résultat de sécurité signalé. Adverse events occurred in 86% on elamipretide versus 71% on placebo, mostly injection-site reactions.

  5. 05Clinique humaine2024

    Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER

    Thompson WR, et al. · Genetics in Medicine · 168-week open-label extension of the TAZPOWER randomised crossover trial; 10 patients with genetically confirmed Barth syndrome entered, 8 reached week 168; elamipretide 40 mg subcutaneous daily

    Cumulative six-minute walk distance improved by 96.1 m at week 168 relative to open-label extension baseline (P = .003), with improvements also reported in fatigue scores and cardiac function measures. Injection-site reactions were the most common adverse event.

  6. 06Clinique humaine2024

    Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial

    Karaa A, et al. · Orphanet Journal of Rare Diseases · Post hoc genotype-stratified analysis of the phase 3 randomised, double-blind, placebo-controlled MMPOWER-3 trial in primary mitochondrial myopathy

    Participants with mtDNA replisome disorders and those with chronic progressive external ophthalmoplegia showed improvement on the six-minute walk test with elamipretide, whereas the overall trial population did not.

  7. 07Clinique humaine2024

    Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial

    Karanjia R, et al. · Ophthalmology · Phase 2 prospective randomised, double-masked, vehicle-controlled trial; 12 subjects with Leber hereditary optic neuropathy, 52 weeks of topical ophthalmic elamipretide

    The trial did not meet its primary best-corrected visual acuity endpoint; a post hoc analysis reported improvement in central visual field mean deviation.

  8. 08Clinique humaine2023

    Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial

    Karaa A, et al. · Neurology · Phase 3 randomised, double-blind, placebo-controlled trial; 218 participants with primary mitochondrial myopathy (109 elamipretide, 109 placebo), 24 weeks

    Elamipretide did not meet the primary endpoints of change in six-minute walk test distance or fatigue score compared with placebo. The drug was generally well tolerated.

  9. 09Clinique humaine2023

    Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data

    Van den Eynde J, et al. · Orphanet Journal of Rare Diseases · Secondary clustering analysis of the randomised, double-blind, placebo-controlled crossover TAZPOWER trial; 12 patients with Barth syndrome

    Agglomerative hierarchical clustering of longitudinal outcome data separated treatment responders from non-responders within the trial cohort, indicating heterogeneous individual response to elamipretide.

  10. 10Clinique humaine2023

    Interventions with Potential to Mitigate Injection Site Reactions Following Subcutaneous Elamipretide Administration: A Phase 1, Crossover Study

    Bergheanu S, et al. · Authorea Preprints · preprint, not peer reviewed; phase 1 crossover study in healthy adults (N=10) given repeated subcutaneous elamipretide with and without measures to prevent injection-site reactions (topical mometasone, ice, tacrolimus, doxepin, oral diphenhydramine), plus mouse mast-cell experiments

    Topical mometasone before injection significantly reduced induration or swelling and itching without changing elamipretide plasma exposure; oral diphenhydramine reduced induration but 50% reported somnolence, and ice reduced pain but lowered peak concentration and early exposure. Preclinical data suggested that elamipretide triggers injection-site reactions by activating the mast-cell receptor MRGPRX2.

    Résultat de sécurité signalé. The abstract states that injection-site reactions were reported in most subjects in earlier subcutaneous elamipretide studies, and links them to mast-cell activation through MRGPRX2.

  11. 11Clinique humaine2022

    Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.

    Hornby B, et al. · Orphanet J Rare Dis · phase 3 retrospective natural-history comparison: 8 TAZPOWER open-label extension patients vs 19 propensity-matched untreated Barth syndrome controls

    Compared with natural-history controls, elamipretide-treated patients walked about 80-91 m further on the 6-minute walk test at weeks 64 and 76 and showed greater handheld-dynamometry muscle strength and improvements in sit-to-stand and a multi-domain responder index; left ventricular stroke volume increased with treatment but declined in controls.

  12. 12Clinique humaine2022

    Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study.

    Mettu PS, et al. · Ophthalmol Sci · phase 1 single-centre open-label trial (ReCLAIM, noncentral geographic atrophy cohort), n=19 adults aged 55 or older with dry age-related macular degeneration, 24 weeks of subcutaneous elamipretide

    All 19 participants had at least one non-ocular adverse event, all mild (73.7%) or moderate (26.3%), with no serious adverse events; two left the study because of adverse events (conversion to neovascular AMD and an intolerable injection-site reaction). Among the 15 completers, best-corrected visual acuity improved by 4.6 letters and low-luminance acuity by 5.4 letters from baseline, in a study without a control group.

  13. 13Clinique humaine2022

    Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.

    Allingham MJ, et al. · Ophthalmol Sci · phase 1 single-centre open-label trial (ReCLAIM, high-risk drusen cohort), n=21 adults aged 55 or older with intermediate age-related macular degeneration, 24 weeks of subcutaneous elamipretide

    All participants had at least one adverse event, mild (57%) or moderate (43%), most commonly injection-site reactions, with no serious systemic adverse events. Among 18 completers, best-corrected acuity improved by 3.6 letters and low-luminance acuity by 5.6 letters from baseline, while drusen volume, autofluorescence, microperimetry and dark adaptation did not change; there was no control group.

  14. 14Clinique humaine2021

    A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism

    Reid Thompson W, et al. · Genetics in Medicine · Phase 2/3 randomised, double-blind, placebo-controlled crossover trial with open-label extension (TAZPOWER); 12 subjects with Barth syndrome

    The randomised crossover phase did not show a significant difference on primary endpoints, but at 36 weeks of open-label treatment six-minute walk distance improved by 95.9 m and the Barth Syndrome Symptom Assessment total fatigue score improved by 2.1 points.

  15. 15Clinique humaine2021

    In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial

    Roshanravan B, et al. · PLoS One · Randomised, double-blind, placebo-controlled single-dose study; 39 healthy older adults, phosphorus magnetic resonance spectroscopy of skeletal muscle

    A single infusion of elamipretide raised in vivo skeletal muscle mitochondrial energetic capacity relative to placebo immediately after infusion. The study measured a short-term bioenergetic endpoint, not exercise performance.

  16. 16Clinique humaine2020

    A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy

    Karaa A, et al. · Journal of Cachexia, Sarcopenia and Muscle · Randomised, double-blind, placebo-controlled crossover trial (MMPOWER-2); 30 adults with primary mitochondrial myopathy, 4-week treatment periods

    Participants receiving elamipretide reported less fatigue and fewer muscle complaints than on placebo, though objective functional endpoints were not consistently improved.

  17. 17Clinique humaine2020

    Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial

    Butler J, et al. · Journal of Cardiac Failure · Phase 2 randomised, double-blind, placebo-controlled trial; 71 patients with heart failure with reduced ejection fraction, 4 weeks

    Elamipretide was well tolerated but did not improve left ventricular end-systolic volume at 4 weeks compared with placebo.

  18. 18Clinique humaine2019

    Urinary mitochondrial DNA copy number identifies renal mitochondrial injury in renovascular hypertensive patients undergoing renal revascularization: A Pilot Study.

    Eirin A, et al. · Acta Physiol (Oxf) · pilot biomarker analysis of the same renal-stenting trial: patients with renovascular hypertension given intravenous elamipretide (n = 6) or vehicle (n = 8) during renal angioplasty, five healthy volunteers as controls, plus pig experiments

    Urinary mitochondrial DNA copy number, used as a marker of renal mitochondrial injury, rose 24 hours after angioplasty, and this rise was blunted with elamipretide compared with placebo. At 3 months, systolic blood pressure fell and estimated GFR rose only in elamipretide-treated patients.

  19. 19Clinique humaine2019

    The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction.

    Hortmann M, et al. · Eur Heart J Acute Cardiovasc Care · biomarker sub-study of the phase 2a EMBRACE STEMI trial: 19 patients with first anterior STEMI after PCI (10 given elamipretide), 16 healthy blood donors, plus a mouse ischaemia-reperfusion model

    Serum HtrA2, proposed as a marker of mitochondria-driven cardiomyocyte apoptosis, was higher after STEMI than in healthy controls, and median HtrA2 was lower in elamipretide-treated patients than in untreated STEMI patients (496.5 vs 1805.5 pg/mL, P≤0.05). The authors stated that the finding needs validation in a larger trial.

  20. 20Clinique humaine2018

    Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.

    Karaa A, et al. · Neurology · phase 1/2 randomised double-blind placebo-controlled dose-escalation trial (MMPOWER), n=36 adults with primary mitochondrial myopathy, 5 days of intravenous treatment

    The highest dose group walked 64.5 m further on the 6-minute walk test at day 5 versus 20.4 m with placebo (p=0.053), with a significant dose-dependent increase in distance and a significant covariate-adjusted difference; no other efficacy or safety endpoints differed.

  21. 21Clinique humaine2017

    Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.

    Daubert MA, et al. · Circ Heart Fail · randomised double-blind placebo-controlled ascending-dose trial, n=36 with HFrEF (EF <=35%), single 4-hour infusion

    A single infusion was safe and well tolerated with no serious adverse events and stable blood pressure and heart rate; the highest dose cohort showed significant decreases in left ventricular end-diastolic and end-systolic volumes at end of infusion versus placebo.

  22. 22Clinique humaine2017

    Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis.

    Saad A, et al. · Circ Cardiovasc Interv · phase 2a randomised placebo-controlled pilot trial in patients with severe atherosclerotic renal artery stenosis undergoing renal angioplasty and stenting (elamipretide n=6, placebo n=8), intravenous infusion before and during the procedure, 3-month follow-up

    Fractional kidney hypoxia on BOLD MRI 24 hours after stenting rose by 47% with placebo but fell by 6% with elamipretide. At 3 months, stenotic-kidney blood flow rose only in the elamipretide group (P=0.04), and estimated GFR increased more with elamipretide (P=0.003) than with placebo (P=0.11).

  23. 23Clinique humaine2016

    EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention.

    Gibson CM, et al. · Eur Heart J · phase 2a multicentre randomised double-blind placebo-controlled trial (EMBRACE STEMI) in first anterior STEMI undergoing primary PCI

    Intravenous MTP-131 (elamipretide) was safe and well tolerated but did not reduce infarct size by CK-MB area under the curve and did not improve MRI, angiographic, electrocardiographic or clinical outcomes.

  24. 24Animal in vivo2026

    Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model

    Vahle B, et al. · Circulation: Heart Failure · Female Zucker fatty spontaneously hypertensive rats, a model of heart failure with preserved ejection fraction

    In this rat model elamipretide improved whole-muscle contractile function by 8.2-10.9% and prevented fibre atrophy, with the authors attributing the effect to cardiolipin stabilisation. These findings are animal data and have not been reproduced in humans.

  25. 25Animal in vivo2026

    Mitochondrial Targeting by Elamipretide Improves Myocardial Bioenergetics Without Translating into Functional Benefits in HFpEF

    Schauer A, et al. · International Journal of Molecular Sciences · Female obese ZSF1 rats with heart failure with preserved ejection fraction

    Despite modest improvements in mitochondrial respiration, diastolic dysfunction persisted and no structural or functional cardiac benefit was observed in these rats.

  26. 26Animal in vivo2026

    Elamipretide Improves Mitochondrial Function in Mitochondrial Trifunctional Protein-Deficient Mice and Human Fibroblasts

    Vieira Neto E, et al. · Journal of Inherited Metabolic Disease · Mitochondrial trifunctional protein beta-subunit deficient mice plus patient-derived human fibroblasts

    Elamipretide increased exercise endurance in the deficient mice and improved bioenergetics in patient fibroblasts, with the effect apparently independent of changes in cardiolipin content. These are animal and cell findings only.

  27. 27Animal in vivo2013

    The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin

    Birk AV, et al. · Journal of the American Society of Nephrology · Rat kidney ischaemia-reperfusion model with accompanying isolated mitochondria mechanistic work

    SS-31 was shown to bind cardiolipin, protect cristae architecture, restore ATP production and reduce acute kidney injury in this model. This is the foundational paper establishing the cardiolipin mechanism.

  28. 28Revue2026

    Elamipretide: a mitochondria-targeting drug for Barth syndrome

    Villatore A, et al. · Trends in Pharmacological Sciences · Narrative review of elamipretide pharmacology in Barth syndrome following its regulatory approval

    The review summarised how elamipretide stabilises cardiolipin and improves mitochondrial function in Barth syndrome, an X-linked disorder of cardiolipin remodelling.

  29. 29Revue2026

    Elamipretide: First Approval.

    Shirley M · Drugs · drug-approval summary

    Elamipretide received US accelerated approval in September 2025 to improve muscle strength in adult and paediatric patients with Barth syndrome above a minimum body weight, becoming the first disease-specific treatment for Barth syndrome; it remained in phase 3 development for dry age-related macular degeneration and mitochondrial myopathies.

  30. 30Rapport de cas2025

    Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report.

    Ortmann L, et al. · Eur Heart J Case Rep · single case, newborn with Barth syndrome diagnosed in utero and left ventricular ejection fraction of 20% at birth, intravenous then subcutaneous elamipretide from the first weeks of life

    After elamipretide was started, left ventricular ejection fraction improved to near-normal and later to 60%, and the infant was weaned off oxygen and discharged home. Standard oral heart-failure medicines were given alongside, so the case cannot separate the effect of elamipretide.

  31. 31Rapport de cas2025

    Cardiac pathology in a patient with a novel pathogenic variant c.703del (p.Ile235SerfsTer4) of the TAFAZZIN gene.

    Prasanpanich M, et al. · Cardiovasc Pathol · single case, infant with Barth syndrome (novel TAFAZZIN variant) in cardiogenic shock on VA-ECMO, intravenous elamipretide while awaiting heart transplantation

    Intravenous elamipretide, started at three weeks of age and continued until transplantation at five months, was given without significant side effects, and the child remained on subcutaneous elamipretide afterwards. The report describes the pathology of the explanted heart and does not assess efficacy.

  32. 32Rapport de cas2025

    Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.

    Jacob N, et al. · Mol Genet Metab · single case with literature review, infant with prenatally identified Barth syndrome and severe left ventricular non-compaction cardiomyopathy, elamipretide started shortly after birth

    Elamipretide treatment was associated with significant and sustained clinical improvement, and the infant moved to inactive status on the heart transplant list with delisting anticipated. As a single uncontrolled case it cannot establish efficacy.

  33. 33Rapport de cas2024

    Expanded-Access Use of Elamipretide Improves Quality of Life in Patients With Rare Mitochondrial Disorders Characterized by Ophthalmic Symptoms: A Case Series.

    Ansari S, Koenig MK · Clin Case Rep · case series, two patients with progressive mitochondrial disorders with eye involvement (CPEO plus and NARP syndrome), expanded-access elamipretide

    Elamipretide was well tolerated and both patients showed improvement in symptoms while on therapy, as reported by the authors. Two uncontrolled cases cannot establish efficacy.

  34. 34Rapport de cas2024

    Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.

    Patino J, et al. · Clin Case Rep · single case, 17-year-old with membrane protein-associated neurodegeneration, expanded-access elamipretide

    During elamipretide treatment the patient's dysarthria, dysphagia and gait improved symptomatically, with objective gains on the 6-minute walk and 5 times sit-to-stand tests. As a single uncontrolled case it cannot establish efficacy.

  35. 35Rapport de cas2024

    Expanded-access use of elamipretide in a critically ill patient with Barth syndrome.

    Goldstein AC, et al. · Genet Med Open · single case, critically ill patient with Barth syndrome, expanded-access elamipretide

    The registry record has no abstract; the title reports expanded-access elamipretide use in a critically ill patient with Barth syndrome. Results are not available in the abstract.

  36. 36Rapport de cas2023

    Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases.

    Koenig MK, et al. · JIMD Rep · case series from a compassionate-use programme, children under 12 years with rare mitochondrial disorders

    The abstract describes elamipretide use in children younger than 12 years with mitochondrial disorders in order to provide dosing parameters and reports no outcome data; results are not available in the abstract.

Limites

Ce que ces preuves n'établissent pas.

Elamipretide's only approved indication is Barth syndrome, granted under accelerated approval on a muscle-strength surrogate endpoint in a very small cohort, and confirmatory clinical benefit has not yet been demonstrated; the largest randomised trial in primary mitochondrial myopathy (MMPOWER-3, n=218) missed its primary endpoints, as did the phase 2 heart failure and Leber hereditary optic neuropathy trials. There are no controlled trials of elamipretide in healthy individuals for exercise capacity, athletic performance, longevity or body composition, and long-term safety data outside the small Barth syndrome cohorts are limited.

Questions courantes sur la recherche.

What is SS-31?

SS-31, also called elamipretide, is a mitochondria-targeted tetrapeptide from the Szeto-Schiller series. It concentrates in the inner mitochondrial membrane and binds the phospholipid cardiolipin, and it is one of the more clinically advanced investigational compounds in mitochondrial research.

Is SS-31 an antioxidant?

It was originally characterised that way, but the mechanism described in the current literature is more specific. Rather than scavenging free radicals in bulk, the peptide binds cardiolipin, stabilises cristae curvature, and prevents cardiolipin-bound cytochrome c from acquiring peroxidase activity — reduced oxidative stress follows from the structural interaction rather than from direct scavenging.

How does SS-31 differ from NAD+ in mitochondrial research?

They address different layers of the same system. SS-31 acts on the physical architecture of the inner membrane through cardiolipin binding, whereas NAD+ work concerns the redox cofactor pool that feeds the electron transport chain and the NAD+-consuming enzymes. The two are frequently discussed side by side in mitochondrial-ageing reviews.

Disponible dans notre catalogue

À des fins de recherche uniquement. Non destiné à la consommation humaine, au diagnostic, au traitement ou à la prévention de toute condition. Rien sur cette page ne constitue un avis médical, et aucune étude résumée ici ne doit être considérée comme une recommandation.